83 related articles for article (PubMed ID: 10745488)
1. Coronary revascularization and aggressive lipid lowering.
Pershad A; Kratzer S; Cooper A
J Invasive Cardiol; 1999 Feb; 11(2):87-9. PubMed ID: 10745488
[No Abstract] [Full Text] [Related]
2. [AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
Z Kardiol; 1999 Mar; 88(3 Suppl):1-4. PubMed ID: 10330699
[No Abstract] [Full Text] [Related]
3. Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial.
Koren MJ
Am J Med; 2005 Dec; 118 Suppl 12A():16-21. PubMed ID: 16356803
[TBL] [Abstract][Full Text] [Related]
4. Aggressive lipid-lowering in stable patients with coronary artery disease.
Supanich B
J Fam Pract; 1999 Oct; 48(10):749-50. PubMed ID: 12224668
[No Abstract] [Full Text] [Related]
5. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Landry P; Dimitri E; Tessier S; Légaré N
J Clin Psychopharmacol; 2008 Jun; 28(3):348-9. PubMed ID: 18480696
[No Abstract] [Full Text] [Related]
6. [Arterial hypertension - the specific case].
Weisser B; Düsing R; Mengden T
Dtsch Med Wochenschr; 2001 Nov; 126(44):1235. PubMed ID: 11687982
[No Abstract] [Full Text] [Related]
7. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
Kuryata OV; Yegorova YV
Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
[TBL] [Abstract][Full Text] [Related]
8. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Nadar S; Lim HS; Beevers DG; Lip GY
J Hum Hypertens; 2002 Dec; 16(12):815-7. PubMed ID: 12522461
[No Abstract] [Full Text] [Related]
9. Reversal of atherosclerosis with aggressive lipid lowering.
Farmer JA
Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
[No Abstract] [Full Text] [Related]
10. The hidden effects of antihypertensive and lipid-lowering agents on the prevention and regression of atherogenesis: new management strategies.
Weinberg MS
R I Med; 1995 Mar; 78(3):78-81. PubMed ID: 7734758
[No Abstract] [Full Text] [Related]
11. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
13. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?
Beevers DG; Lee KW; Lip GY
J Hum Hypertens; 2003 Jun; 17(6):367-72. PubMed ID: 12764397
[No Abstract] [Full Text] [Related]
14. [Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
MMW Fortschr Med; 2001 Apr; 143(14):44. PubMed ID: 11340911
[No Abstract] [Full Text] [Related]
15. Caduet treats two cardiovascular conditions at once.
Wimett L; Laustsen G
Nurse Pract; 2004 Jun; 29(6):56-7. PubMed ID: 15257126
[No Abstract] [Full Text] [Related]
16. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
[TBL] [Abstract][Full Text] [Related]
17. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Nordøy A
Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168
[TBL] [Abstract][Full Text] [Related]
18. A closer look at Caduet. The new generation of combination treatment.
Brock CM; Pitcock J
Adv Nurse Pract; 2005 Jan; 13(1):31-3. PubMed ID: 15679289
[No Abstract] [Full Text] [Related]
19. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
